You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Last Updated: September 30, 2023

Mylan Institutional Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MYLAN INSTITUTIONAL, and what generic and branded alternatives to MYLAN INSTITUTIONAL drugs are available?

MYLAN INSTITUTIONAL has forty-six approved drugs.

Summary for Mylan Institutional

US Patents:	0
Tradenames:	41
Ingredients:	39
NDAs:	46
Patent Litigation for Mylan Institutional:	See patent lawsuits for Mylan Institutional
PTAB Cases with Mylan Institutional as petitioner:	See PTAB cases with Mylan Institutional as petitioner

Drugs and US Patents for Mylan Institutional

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Institutional	MEFOXIN	cefoxitin sodium	INJECTABLE;INJECTION	062757-002	Jan 8, 1987		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Mylan Institutional	DURACLON	clonidine hydrochloride	INJECTABLE;INJECTION	020615-002	Apr 27, 1999		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Mylan Institutional	EPIRUBICIN HYDROCHLORIDE	epirubicin hydrochloride	INJECTABLE;INJECTION	065371-002	Nov 28, 2007		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Mylan Institutional	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	202881-001	Aug 18, 2014	AP	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Mylan Institutional

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan Institutional	ENLON-PLUS	atropine sulfate; edrophonium chloride	INJECTABLE;INJECTION	019677-001	Nov 6, 1991	4,952,586	⤷ Try a Trial
Mylan Institutional	ULTIVA	remifentanil hydrochloride	INJECTABLE;INJECTION	020630-003	Jul 12, 1996	5,019,583*PED	⤷ Try a Trial
Mylan Institutional	ULTIVA	remifentanil hydrochloride	INJECTABLE;INJECTION	020630-003	Jul 12, 1996	5,466,700*PED	⤷ Try a Trial
Mylan Institutional	ULTIVA	remifentanil hydrochloride	INJECTABLE;INJECTION	020630-002	Jul 12, 1996	5,866,591*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	100 mg/mL, 2.5 mL vials	➤ Subscribe	2007-09-24
➤ Subscribe	for Injection	1 mg/vial, 2 mg/vial and 5 mg/vial	➤ Subscribe	2013-12-27
➤ Subscribe	Injection	1 mg/mL, 50 mL vials	➤ Subscribe	2011-12-16

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Moodys

McKesson

AstraZeneca

Baxter

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.